# GSK239512 DDI Study

> **NCT01802931** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 22 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** GSK239512
- **DRUG:** ketoconazole

## Key facts

- **NCT ID:** NCT01802931
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-07
- **Primary completion:** 2013-04-15
- **Final completion:** 2013-04-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802931, "GSK239512 DDI Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01802931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*